Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
About this episode
This episode explores the role of KIT-targeted TKIs in treating indolent systemic mastocytosis and discusses emerging therapies and personalized treatment approaches.
CME credits: 0.25 Valid until: 31-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/navigating-today-and-shaping-tomorrow-in-ism-personalized-strategies-with-current-and-emerging-kit-inhibitors/54388/ This online educational activity explores the evolving role of KIT-targeted tyrosine kinase inhibitors (TKIs) in indolent systemic mastocytosis (ISM). Expert faculty discuss pivotal clinical data supporting the approval of avapritinib, a potent TKI that targets KIT D816V, in patients with ISM. They also highlight emerging clinical evidence on next-generation KIT TKIs, such as elenestinib and bezuclastinib, that are designed for enhanced selectivity and minimal brain penetration. Finally, faculty discuss how these agents may be sequenced and integrated into a personalized, multidisciplinary treatment approach aimed at durable symptom control and improved quality of life for patients with ISM. =
Topics covered
- KIT-targeted tyrosine kinase inhibitors
- indolent systemic mastocytosis
- personalized treatment strategies
- clinical data
- next-generation TKIs
- symptom control
- quality of life
Keywords
- KIT inhibitors
- tyrosine kinase inhibitors
- avapritinib
- elenestinib
- bezuclastinib
- systemic mastocytosis
- clinical evidence
- treatment approach
- symptom control
- quality of life
Mentioned in this episode
Organizations: ReachMD
Products: avapritinib, elenestinib, bezuclastinib
More episodes of ReachMD CME
- Living With Systemic Mastocytosis: Bridging Clinical Decisions and Patient Realities
- Beyond IOP: Integrating Ocular Surface Resilience Into Glaucoma Management
- Retina Rumble: Debating Modern Treatment Options
- Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
- Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
- The Future of HNSCC: Aligning Teams, Transforming Care
Explore listener stats, chart rankings, contacts and more on the ReachMD CME podcast page.